Free Newsletter
Lilly's Cialis price hikes didn't dent demand
Free newsletter via e-mail
Tools
One of the more interesting parts of Eli Lilly's Q4 earnings report was the section on Cialis, the ED drug. Lilly has doubled its price since its launch, yet that hasn't dampened demand. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: